Travere Therapeutics, Inc. (NASDAQ:TVTX) is among the 10 Best Growth Stocks Under $100 to Buy Now. HC Wainwright & Co., a ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on June 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to 15 new employees, consisting ...

Travere Therapeutics (NASDAQ:TVTX), a biopharmaceutical company focused on developing therapies for rare diseases, finds itself at a critical juncture as it navigates regulatory challenges and ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on June 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to 15 new employees ...

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Travere Therapeutics TVTX in the last three months. In the table below, you'll find a ...

Discover six kidney disease companies actively working on innovative treatments that could make a difference to patients' lives.

Detailed price information for Ovid Therapeutics Inc (OVID-Q) from The Globe and Mail including charting and trades.

H.C. Wainwright analysts assumed coverage on Travere Therapeutics (NASDAQ:TVTX) with a Buy rating on Wednesday, setting a price target of $30.00. This aligns with the broader Wall Street sentiment ...